You are here

Imprimis to Offer Compounded Alternative to Restasis

Announcement follows judge’s ruling to toss patents

Days after a federal judge threw out patents on the dry-eye medicine Restasis (Allergan), a San Diego pharmaceutical company said it would offer a cheaper compounded version of cyclosporine. Shares of Imprimis Pharmaceuticals nearly doubled after the announcement.

Allergan last month sued Imprimis alleging the company is illegally manufacturing and selling unapproved new drugs. Imprimis called the lawsuit frivolous and a tactic to snuff out competition offering lower cost options to expensive drugs, Reuters reported.

The Imprimis product will cost 99 cents for a month’s supply and refills start at $79 a month.

Allergan recently stirred controversy after striking a deal with a Native American tribe that would shield certain patents on Restasis, which can cost $5,000 a year according to Imprimis. A U.S. judge Monday invalidated those patents on Restasis on the grounds that they cover ideas that are obvious.

Imprimis  said its compounded cyclosporine-based formulations are made from FDA-approved drug components and compounded in FDA-inspected facilities, require a patient-specific prescription, and may be customized according to patients' individual needs.

Topical cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when purchased in the commercially available form of Restasis, Imprimis said. 

Sources: Reuters; October 19, 2017; Imprimis; October 19, 2017.

More Headlines

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Growing opioid crisis fueling suicide increase according to study
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics